Direct-Acting Antiviral Medicines Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Liver Cirrhosis and Hepatocellular Carcinoma
- Growing Investment in the Development of Advanced Therapies
Challenges
- Low Access to Direct-Acting Antiviral Medicines in Low Economic Regions
- Side Effects of Direct-Acting Antiviral Medicines
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Direct-Acting Antiviral Medicines Market size is likely to register remarkable growth rate during the forecast period i.e., between 2025-2037.
Increasing prevalence of liver cirrhosis and hepatocellular carcinoma and the growing investment in the development of advanced therapies will drive the market growth.
Asia Pacific industry is set to account for largest revenue share by 2037, owing to increasing hepatitis C infection prevalence and rising focus of major companies for expanding their product to countries in the region.
The major players in the market are AbbVie, Inc., Janssen Therapeutics, Bristol-Myers Squibb, and Merck & Co., among others.
